SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: DewDiligence_on_SI who wrote (3439)2/13/2022 12:35:06 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3557
 
Do not know. CANDELA study does not describe P2 trial extension, it should be 16 + 32 =48 weeks??



To: DewDiligence_on_SI who wrote (3439)2/13/2022 1:02:49 PM
From: Miljenko Zuanic1 Recommendation

Recommended By
CuttingEdge Bio

  Respond to of 3557
 
investor.regeneron.com
Initial data (if hold in p3) demonstrate that Eylea 8 mg is better than Vabysmo 6 mg (relative to Eylea 2 mg) on 12/16 weeks intervals!
And Mr. Market took notice on it. :-)